Investor Relations

Home
Investor Relations
Important Notice

Announcement

Senhwa's drug CX-5461 is being evaluated for the first time in combination with AstraZenecaDaiichi Sankyo's ADC, trastuzumab deruxtecan, in a Phase 1b clinical trial for HER2-positive solid tumors and breast cancer

Download

Dec: 29; 2025

Senhwa Biosciences, Inc. will attend the institutional investor conference invited by Cathay Securities Corporation.

1.Date of institutional investor conference:2025/12/23
2.Time of institutional investor conference: 14:00 (Taiwan time)
3.Location of institutional investor conference: 18F, No. 333, Sec. 2, Dunhua S. Rd., Da'an Dist., Taipei City, Taiwan(Cathay Securities Headquarters)
4.Outline of institutional investor conference: The Company will attend Cathay Securities' investor conference to update the Company's business operations.
5.Any other matters that need to be specified: None. Related information will be disclosed on MOPS

Conference video link: https://youtu.be/dppsCUH5Vyw

Download

Dec: 17; 2025